Antidepressive Agents, Second-Generation - Research News and Information

Wednesday, January 07, 2009

Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial.

29 Sep 2008 BACKGROUND: Late-life depression is associated with chronic illness, disability, and a poor prognosis. Primary care management may be in need of improvement. AIM: To compare the effects of an intervention programme that aims to improve the ... Read more...

[Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives]

15 Sep 2008 Despite a better overall tolerance as compared to classical antipsychotics, atypical antipsychotics are not devoid of side-effects, notably metabolic factors (weight gain, alteration of lipid and glucose profile). These side-effects are very ... Read more...

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

30 Aug 2008 The objective of this study was to assess the efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) 50 and 100 mg/day for major depressive disorder (MDD). A multicenter, randomized, double-blind, ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Antidepressive Agents, Second-Generation'

These are the very latest articles for this heading:

• The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light? 30 Oct 2008
• Should paroxetine be used to treat depression during pregnancy? 30 Oct 2008
• Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial. 29 Sep 2008
• [Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives] 15 Sep 2008
• Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. 30 Aug 2008
• A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. 30 Aug 2008
• Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale. 30 Aug 2008
• Bupropion-induced angioedema. 30 Aug 2008
• Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. 30 Aug 2008
• [Case of the month. A malignant brain tumor presenting with depression and hallucinations] 30 Aug 2008
• Severe constipation associated with extended-release bupropion therapy. 13 Aug 2008
• A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. 9 Aug 2008
• [A place for SSRIs in the treatment of severely depressed children and adolescents] 31 Jul 2008
• Bupropion-induced hypomania in a patient with unipolar depression. 30 Jul 2008
• Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 30 Jul 2008
• Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. 30 Jul 2008
• Renal failure in a depressed adolescent on escitalopram. 30 Jul 2008
• Why we should use simpler models if the data allow this: relevance for ANOVA designs in experimental biology. 19 Jul 2008
• Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice. 19 Jul 2008
• Evaluation of the repeated open-space swim model of depression in the mouse. 17 Jul 2008

See a longer list of these articles.

Technical information about 'Antidepressive Agents, Second-Generation'

Definition: A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Registry Number: 0

Descriptor UI: D018687

Alternative terms: Antidepressive Agents, Second-Generation; Antidepressive Agents, Second Generation; Antidepressive Drugs, Second-Generation; Antidepressive Drugs, Second Generation; Drugs, Second-Generation Antidepressive; Second-Generation Antidepressive Drugs; Atypical Antidepressants; Second-Generation Antidepressive Agents; Agents, Second-Generation Antidepressive; Second Generation Antidepressive Agents; Antidepressants, Atypical;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.427.700.122.050;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics